Loading...
•
Dec 31, 2024
Shattuck Labs Q4 2024 Earnings Report
Shattuck Labs reported a wider net loss in Q4 2024 with flat R&D spending and slightly reduced G&A expenses, while holding a strong cash position.
Key Takeaways
In Q4 2024, Shattuck Labs reported no revenue and a net loss of $18.68 million, or -$0.37 per share. Operating expenses remained stable, with R&D and G&A expenses similar to the previous year. The company held $73 million in cash and investments at quarter-end, expected to fund operations into 2027.
Net loss for Q4 2024 was $18.68 million, or -$0.37 per share.
R&D expenses were $15.4 million, nearly unchanged from the prior year.
G&A expenses declined slightly to $4.2 million from $4.4 million.
Cash and investments totaled $73 million, providing runway into 2027.
Shattuck Labs
Shattuck Labs
Forward Guidance
Shattuck expects to initiate clinical development of SL-325 in 2025 and maintain financial runway into 2027.
Positive Outlook
- SL-325 preclinical data showed favorable safety and full DR3 receptor occupancy.
- IND filing for SL-325 expected in Q3 2025.
- Cash runway supports operations into 2027.
- Focus on DR3-targeted therapies for IBD and immune diseases.
- Potential first-in-class antibody with strong preclinical profile.
Challenges Ahead
- No revenue reported in Q4 2024.
- Net loss widened slightly from previous year.
- Termination of SL-172154 program reduced pipeline breadth.
- Cash position declined significantly year-over-year.
- Pipeline dependent on success of upcoming IND and Phase 1 trial.